As a consequence, PSMA-PET is currently performed in a relatively small number of diagnostic centers and we believe that [18F]fluoromethylcholine will remain the most widespread radiopharmaceutical for prostate cancer imaging for a long time to come. The gene discussed is FOLH1; the disease is prostate cancer.